The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain
Open accessAbstract
BACKGROUND: There is a clear need to develop an objective diagnostic test for Alzheimer disease (AD). Changes in the levels of cerebrospinal fluid (CSF) tau protein and beta-amyloid 42 (Abeta42) peptide in patients with AD have been well documented, but the relationship between these biomarkers and neuropathologic changes in the brain is not established. OBJECTIVE: To study the relationship between antemortem CSF biomarker levels and Alzheimer-type neuropathologic changes in the brain. DESIGN: Cross-sectional study to correlate levels of CSF Abeta42, total tau, and phosphorylated tau protein with neuropathologic changes in the brain. SETTING: Academic research. Patients The study included 123 patients (79 with clinically diagnosed AD, 29 with other dementia, and 15 with other neurologic disease). All underwent clinical evaluation and provided antemortem lumbar CSF samples, and neuropathologic data were collected from September 11, 1990, to March 13, 2003, in the Department of Neuroscience and Neurology, University of Kuopio, Kuopio, Finland. MAIN OUTCOME MEASURES: Levels of CSF Abeta42, total tau, and phosphorylated tau protein were measured using standard commercial immunoassays. Neuropathologic evaluations included the classic silver impregnation method and immunohistochemistry for Abeta, hyperphosphorylated tau, and alpha-synuclein. RESULTS: Cerebrospinal fluid Abeta42 and tau protein levels were related to amyloid load and the presence of neurofibrillary pathologic abnormalities in the brain. Cerebrospinal fluid Abeta42 level correlated inversely with total Abeta load in the brain, and CSF tau level correlated with results of immunohistochemistry for hyperphosphorylated tau and with the presence of neocortical neurofibrillary tangles. In multivariate logistic regression analysis, the number of neuritic plaques in the brain remained a significant predictor of decreased CSF Abeta42 level and of increased CSF tau level. Based on the ratio of phosphorylated tau level to Abeta42 level, sensitivity was 91.6%, and specificity was 85.7%, with an overall accuracy of 90.2% for the presence of pathologic neuritic plaque in the brain. CONCLUSIONS: Cerebrospinal fluid Abeta42 and tau proteins are biomarkers of AD-associated pathologic changes in the brain. The combination of abnormally low CSF Abeta42 level and abnormally high CSF tau level predicted the presence of AD pathologic features with high accuracy. This combination assay may be helpful in diagnosing the presence of AD pathologic changes in the brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A characteristic biomarker profile, defined by reduced levels of Aβ42 in conjunction with elevated t-tau and p-tau, provides a robust biochemical signature for detecting AD pathology and distinguishing it from other neurodegenerative disorders72,73.”
From Artificial intelligence-driven multi-omics approaches in Alzheimer's disease: Progress, challenges, and future directions (2025) · cites this paper as [73]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Given that a CSF Aβ42 concentration lower than 500 pg/mL has been utilized as a reliable threshold for the presence of cerebral Aβ deposition in humans (7, 19, 22, 26)”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [26]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The level of CSF P-tau also does correlate with severity of PHF tau accumulation after death [81,150].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [150]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D. L., & Stadlan, E. (2011) · Neurology · doi:10.1212/01.wnl.0000400650.92875.cf · Cited by 9,882
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria
Neary, D., Snowden, J. S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., Kertesz, A., Robert, P. H., Albert, M., et al. (1998) · Neurology · doi:10.1212/wnl.51.6.1546 · Cited by 5,047
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172
Self-citationHansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700
Cited by
Sorted by citations
Items 501–600 of 895
Testa, G., Giannelli, S., Sottero, B., Staurenghi, E., Giaccone, G., Caroppo, P., Gamba, P., & Leonarduzzi, G. (2023) · Antioxidants · doi:10.3390/antiox12030631 · Cited by 20
Tau: a biomarker of Huntington’s disease
Lepinay, E., & Cicchetti, F. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02230-9 · Cited by 19
Muñoz‐Ruiz, M. Á., Hartikainen, P. H., Hall, A., Mattila, J., Koikkalainen, J. R., Herukka, S., Julkunen, V., Vanninen, R. L., Liu, Y., Lötjönen, J. M. P., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-122260 · Cited by 18
Self-citationBoutoleau‐Bretonnière, C., Lebouvier, T., Delaroche, O., Lamy, E., Evrard, C., Charriau, T., Bretonnière, C., Damier, P., Derkinderen, P., & Vercelletto, M. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110761 · Cited by 18
Driving and dementia: a clinician's guide
Wilson, S., & Pinner, G. (2013) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.111.009555 · Cited by 19
Yang, S., Chieh, J.-J., Yang, C. C. C.-C., Liao, S. H., Chen, H. H., Horng, H. E., Yang, H. C., Hong, C., Chiu, M., Chen, T., et al. (2012) · IEEE Transactions on Applied Superconductivity · doi:10.1109/tasc.2012.2229772 · Cited by 18
Zhang, Y., Lin, Y., Liu, Q., Yuan, X., Anqiong, M., Liu, Y., Li, Q., Zheng, J., Hu, B., & Yu, F. (2018) · BioMed Research International · doi:10.1155/2018/4014021 · Cited by 18
Constantinides, V. C., Paraskevas, G. P., Efthymiopoulou, E., Stefanis, L., & Kapaki, E. N. (2019) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2019.01.046 · Cited by 18
Ahnaou, A., Rodriguez-Manrique, D., Biermans, R., Embrechts, S., Manyakov, N. V., & Drinkenburg, W. H. I. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155431 · Cited by 18
Tokumitsu, K., Yasui‐Furukori, N., Takeuchi, J. S., Yachimori, K., Sugawara, N., Terayama, Y., Tanaka, N., Naraoka, T., & Shimoda, K. (2021) · PLoS ONE · doi:10.1371/journal.pone.0247427 · Cited by 18
Wang, X., Xiong, Y., Yang, Y., Tuo, Q., Wang, X., Chen, R., Tian, Q., Zhang, Z.-P., Yan, X., Yang, Z.-Y., et al. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.02.022 · Cited by 18
Harris, P., Suarez, M. F., Surace, E. I., Méndez, P. C., Martin, M. E., Clarens, M. F., Tapajóz, F., Campos, J., Sevlever, G. E., Allegri, R., et al. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s84292 · Cited by 19
Analysis of Human Tau in Cerebrospinal Fluid
Hanisch, K., Soininen, H., Alafuzoff, I., & Hoffmann, R. (2010) · Journal of Proteome Research · doi:10.1021/pr901002t · Cited by 17
Self-citationDiagnostic Assessment in Primary Progressive Aphasia: An Illustrative Case Example
Europa, E., Iaccarino, L., Perry, D. C., Weis, E., Welch, A. E., Rabinovici, G. D., Miller, B. L., Gorno‐Tempini, M. L., & Henry, M. L. (2020) · American Journal of Speech-Language Pathology · doi:10.1044/2020_ajslp-20-00007 · Cited by 18
OCTA in neurodegenerative optic neuropathies: emerging biomarkers at the eye–brain interface
Asanad, S., Mohammed, I. S. K., Sadun, A. A., & Saeedi, O. J. (2020) · Therapeutic Advances in Ophthalmology · doi:10.1177/2515841420950508 · Cited by 17
Critical Comparison of Different Biomarkers for Alzheimer’s Disease in a Clinical Setting
Weise, D., Tiepolt, S., Awissus, C., Hoffmann, K., Lobsien, D., Kaiser, T., Barthel, H., Sabri, O., & Gertz, H. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150229 · Cited by 18
Frontotemporal dementia is the leading cause of “true” A−/T+ profiles defined with Aβ42/40 ratio
Pouclet‐Courtemanche, H., Nguyen, T., Skrobala, E., Boutoleau‐Bretonnière, C., Pasquier, F., Bouaziz-Amar, É., Bigot‐Corbel, E., Schraen‐Maschke, S., Dumurgier, J., Paquet, C., et al. (2019) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.01.001 · Cited by 18
Shin, W. S., Di, J., Murray, K. A., Sun, C., Li, B., Bitan, G., & Jiang, L. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00268 · Cited by 17
RetractedAlzheimer's Disease Diagnosis Using Misfolding Proteins in Blood
Lee, H., Ugay, D. A., Hong, S., & Kim, Y. S. (2020) · Dementia and Neurocognitive Disorders · doi:10.12779/dnd.2020.19.1.1 · Cited by 17
Is liquid biopsy mature enough for the diagnosis of Alzheimer’s disease?
Gong, X., Zhang, H., Liu, X., Liu, Y., Liu, J., Fapohunda, F. O., Lü, P., Wang, K., & Tang, M. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.977999 · Cited by 17
Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in Alzheimer Dementia
Spitzer, P., Schieb, H., Kamrowski‐Kruck, H., Otto, M., Chiasserini, D., Parnetti, L., Herukka, S., Schuchhardt, J., Wiltfang, J., & Klafki, H. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/739847 · Cited by 18
Self-citationEdsbagge, M., Andreasson, U., Ambarki, K., Wikkelsø, C., Eklund, A., Blennow, K., Zetterberg, H., & Tullberg, M. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-161257 · Cited by 17
Cerebrospinal fluid biomarkers of malignancies located in the central nervous system
Verheul, C., Kleijn, A., & Lamfers, M. L. M. (2017) · Handbook of clinical neurology · doi:10.1016/b978-0-12-804279-3.00010-1 · Cited by 17
Skoog, I. G., Kern, S., Zetterberg, H., Östling, S., Börjesson‐Hanson, A., Guo, X., & Blennow, K. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170950 · Cited by 18
Giacomucci, G., Mazzeo, S., Bagnoli, S., Casini, M., Padiglioni, S., Polito, C., Berti, V., Balestrini, J., Ferrari, C., Lombardi, G., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11010047 · Cited by 16
The contributions of metabolomics in the discovery of new therapeutic targets in Alzheimer's disease
Samey, R. A., Antier, D., Mavel, S., Dufour‐Rainfray, D., Balageas, A., Beaufils, É., Emond, P., Foucault‐Fruchard, L., & Chalon, S. (2021) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12654 · Cited by 16
Tomassen, J., den Braber, A., van der Landen, S. M., Konijnenberg, E., Teunissen, C. E., Vermunt, L., de Geus, E. J. C., Boomsma, D. I., Scheltens, P., Tijms, B. M., et al. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12346 · Cited by 16
Exacerbated CSF abnormalities in younger patients with Alzheimer's disease
Dumurgier, J., Gabelle, A., Vercruysse, O., Bombois, S., Laplanche, J., Peoc’h, K., Schraen‐Maschke, S., Sablonnière, B., Pasquier, F., Touchon, J., et al. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.01.023 · Cited by 17
Clinical Aspects of Alzheimer’s Disease
Kumfor, F., Halliday, G. M., & Piguet, O. (2017) · Advances in neurobiology · doi:10.1007/978-3-319-57193-5_2 · Cited by 16
Rinne, J. O., Suotunen, T., Rummukainen, J. K., Herukka, S., Nerg, O., Koivisto, A. M., Rauramaa, T. H., Någren, K., Hiltunen, M., Alafuzoff, I. I., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180645 · Cited by 16
Self-citationDelatour, B., Epelbaum, S., Petiet, A., & Dhénain, M. (2010) · International Journal of Alzheimer s Disease · doi:10.4061/2010/604853 · Cited by 18
Illustrated Neuropathologic Diagnosis of Alzheimer’s Disease
Doher, N., Davoudi, V., Magaki, S., Townley, R. A., Haeri, M., & Vinters, H. V. (2023) · Neurology International · doi:10.3390/neurolint15030054 · Cited by 16
Smith, R. G., Pishva, E., Kouhsar, M. P., Imm, J. L., Dobričić, V., Johannsen, P., Wittig, M., Franke, A., Vandenberghe, R. R., Schaeverbeke, J. M., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14098 · Cited by 15
McKenna, M. R., Gbadeyan, O., Andridge, R., Schroeder, M. W., Pugh, E., Scharre, D. W., & Prakash, R. S. (2025) · Neuropsychology · doi:10.1037/neu0000987 · Cited by 16
Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease
Zetterberg, H., Mattsson, N., Blennow, K., & Olsson, B. (2010) · Alzheimer s Research & Therapy · doi:10.1186/alzrt56 · Cited by 15
Aβ and the dementia syndrome: Simple versus complex perspectives
Hunter, S., Smailagic, N., & Brayne, C. (2018) · European Journal of Clinical Investigation · doi:10.1111/eci.13025 · Cited by 15
Hok‐A‐Hin, Y. S., Hoozemans, J. J. M., Hu, W. T., Wouters, D., Howell, J. C., Rábano, A., van der Flier, W. M., Pijnenburg, Y. A. L., Teunissen, C. E., & del Campo, M. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01039-y · Cited by 16
Mapping CSF biomarker profiles onto NIA–AA guidelines for Alzheimer’s disease
Alexopoulos, P., Roesler, J., Thierjung, N., Werle, L., Buck, D., Yakushev, I. Y., Gleixner, L. S., Kagerbauer, S. M., Ortner, M., Grimmer, T., et al. (2015) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-015-0628-7 · Cited by 17
White Matter Lesions Are Not Related toβ-Amyloid Deposition in an Autopsy-Based Study
Rutten‐Jacobs, L. C. A., de Leeuw, F., van Bon, L. G., de Gouberville, M. C. G., Schepens‐Franke, A. N., Dederen, P. J. W. C., Spliet, W. G. M., Wesseling, P., & Kiliaan, A. J. (2011) · Current Gerontology and Geriatrics Research · doi:10.1155/2011/826862 · Cited by 15
Kim, H. J., Kim, J., Cho, H., Ye, B. S., Yoon, C. W., Noh, Y., Kim, G. H., Lee, J. H., Kim, J. S., Choe, Y. S., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075602 · Cited by 15
Matthews, B. R. (2010) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000368210.41093.4e · Cited by 15
DeMarshall, C. A., Oh, E. S., Kheirkhah, R., Sieber, F. E., Zetterberg, H., Blennow, K., & Nagele, R. G. (2019) · PLoS ONE · doi:10.1371/journal.pone.0225178 · Cited by 16
Imaging and biomarkers for Alzheimer's disease
Allan, C. L., Sexton, C. E., Welchew, D., & Ebmeier, K. P. (2010) · Maturitas · doi:10.1016/j.maturitas.2009.12.006 · Cited by 15
Kaipainen, A. L., Jääskeläinen, O., Liu, Y., Haapalinna, F., Nykänen, N., Vanninen, R. L., Koivisto, A. M., Julkunen, V., Remes, A. M., & Herukka, S. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200175 · Cited by 15
Self-citationCSF β-Amyloid and Tau Biomarker Changes in Veterans With Mild Traumatic Brain Injury
Li, G., Iliff, J. J., Shofer, J. B., Mayer, C. L., Meabon, J. S., Cook, D. G., Pagulayan, K. F., Raskind, M. A., Zetterberg, H., Blennow, K., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000209197 · Cited by 14
Cheng, Y., Ho, E., Weıntraub, S., Rentz, D. M., Gershon, R. C., Das, S., & Dodge, H. H. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.77 · Cited by 14
Biomarcadores en la enfermedad de Alzheimer
Ribas, G. G., López-Sendón, J. L., & Caldentey, J. G. (2014) · Revista de Neurología · doi:10.33588/rn.5807.2013394 · Cited by 14
Allison, S. L., Jonaitis, E. M., Koscik, R. L., Hermann, B. P., Mueller, K. D., Cary, R. P., Ma, Y., Rowley, H. A., Carlsson, C. M., Asthana, S., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.01.030 · Cited by 15
Monge-Argilés, J. A., Muñoz‐Ruiz, C., Pampliega-Pérez, A., Gómez-López, M. J., Sánchez–Payá, J., Borja, E. R., Ruiz-Vegara, M., Montoya, J., & Leiva-Santana, C. (2011) · Neurochemical Research · doi:10.1007/s11064-011-0438-x · Cited by 15
Schierle, G. S. K., Michel, C. H., & Gasparini, L. (2016) · Microscopy Research and Technique · doi:10.1002/jemt.22698 · Cited by 14
Plagg, B., Marksteiner, J., Kniewallner, K. M., & Humpel, C. (2015) · Biogerontology · doi:10.1007/s10522-015-9580-1 · Cited by 14
Amyloid imaging in the prediction of Alzheimer-type dementia in subjects with amnestic MCI
Visser, P. J., & Knopman, D. S. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b61b5d · Cited by 14
Associations of Neprilysin Activity in CSF with Biomarkers for Alzheimer’s Disease
Grimmer, T., Goldhardt, O., Yakushev, I., Ortner, M., Sorg, C., Diehl-Schmid, J., Förstl, H., Kurz, A., Perneczky, R., & Miners, S. (2019) · Neurodegenerative Diseases · doi:10.1159/000500811 · Cited by 13
Deng, Z., Chen, H., Chen, J., Du, Z., Zhou, W., & Yuan, Z. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167960 · Cited by 14
Ahn, J.-S., & Jang, C. (2024) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2024.114211 · Cited by 13
AI-Based Classification of Mild Cognitive Impairment and Cognitively Normal Patients
Christodoulou, R. C., Christofi, G., Pitsillos, R., Ibrahim, R., Papageorgiou, P. S., Papageorgiou, S. G., Vassiliou, E. K., & Georgiou, M. F. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14155261 · Cited by 13
Patel, S. (2012) · Expert Review of Proteomics · doi:10.1586/epr.12.25 · Cited by 13
Initial Memory Deficit Profiles in Patients with a Cerebrospinal Fluid Alzheimer's Disease Signature
Xie, J., Gabelle, A., Dorey, A., Garnier‐Crussard, A., Perret‐Liaudet, A., Delphin‐Combe, F., Bathsavanis, A., Dauphinot, V., Lehmann, S., Mercier, B., et al. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131916 · Cited by 15
Lauridsen, C., Sando, S. B., Shabnam, A., Møller, I., Berge, G., Grøntvedt, G. R., Bakken, I. J., Salvesen, Ø. O., Bråthen, G., & White, L. R. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00030 · Cited by 14
Cerebral microbleeds and CSF Alzheimer biomarkers in primary progressive aphasias
Mendes, A., Bertrand, A., Lamari, F., Olivier Colliot, A., Routier, A., Godefroy, O., Etcharry‐Bouyx, F., Moreaud, O., Pasquier, F., Couratier, P., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005165 · Cited by 13
Is Olfactory Epithelium Biopsy Useful for Confirming Alzheimer’s Disease?
Godoy, M. D. C. L., Fornazieri, M. A., Doty, R. L., Pinna, F. D. R., Farfel, J. M., dos Santos, G. B., Molina, M., Ferretti‐Rebustini, R. E. D. L., Leite, R. E. P., Suemoto, C. K., et al. (2018) · Annals of Otology Rhinology & Laryngology · doi:10.1177/0003489418814865 · Cited by 14
Lilamand, M., Hourrègue, C., & Paquet, C. (2020) · Revue Neurologique · doi:10.1016/j.neurol.2019.12.006 · Cited by 13
Glycemia and Levels of Cerebrospinal Fluid Amyloid and Tau in Patients Attending a Memory Clinic
Exalto, L. G., van der Flier, W. M., Scheltens, P., & Biessels, G. J. (2010) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2010.02854.x · Cited by 13
Loeffler, D. A., Aasly, J. O., LeWitt, P. A., & Coffey, M. P. (2019) · Journal of Parkinson s Disease · doi:10.3233/jpd-191630 · Cited by 13
Paquet, C., Dumurgier, J., & Hugon, J. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00168 · Cited by 15
Role of CSF Biomarkers in the Diagnosis of Prodromal Alzheimer‘s Disease
Parnetti, L., & Chiasserini, D. (2011) · Biomarkers in Medicine · doi:10.2217/bmm.11.48 · Cited by 12
An Exploratory Study of Cognitive Involvement in Hereditary Transthyretin Amyloidosis
Durmuş, H., Çakar, A., Demirci, H., Alaylıoğlu, M., Gezen‐Ak, D., Dursun, E., & Parman, Y. (2021) · Acta Neurologica Scandinavica · doi:10.1111/ane.13507 · Cited by 12
Wang, X., Zhou, X., Uberseder, B., Lee, J., Latimer, C. S., Furdui, C. M., Keene, C. D., Montine, T. J., Register, T. C., Craft, S., et al. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105463 · Cited by 14
de Rino, F., Boneschi, F. M., Caso, F., Zuffi, M., Zabeo, M., Passerini, G., Comı, G., Magnani, G., & Franceschi, M. (2011) · Neurological Sciences · doi:10.1007/s10072-011-0866-z · Cited by 12
Haapalinna, F., Paajanen, T. I., Penttinen, J., Kokki, H. J., Kokki, M., Koivisto, A. M., Hartikainen, P. H., Solje, E., Hänninen, T., Remes, A. M., et al. (2016) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000446425 · Cited by 14
Self-citationCYP2C19 variant mitigates Alzheimer disease pathophysiology in vivo and postmortem
Benedet, A. L., Yu, L., Labbe, A., Mathotaarachchi, S. S., Pascoal, T. A., Shin, M., Kang, M.-S., Gauthier, S. G., Rouleau, G. A., Poirier, J., et al. (2018) · Neurology Genetics · doi:10.1212/nxg.0000000000000216 · Cited by 12
Supporting self-management in early dementia: a contribution towards ‘living well’?
Cheffey, J., Hill, L., Roberts, G. A., & Marlow, R. (2013) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.112.011023 · Cited by 12
Ingber, A. P., Hassenstab, J. J., Fagan, A. M., Benzinger, T. L. S., Grant, E., Holtzman, D. M., Morris, J. C., & Roe, C. M. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150478 · Cited by 12
Studart‐Neto, A., Barbosa, B. J. A. P., Coutinho, A. M., de Souza, L. C., Schilling, L. P., da Silva, M. N. M., Castilhos, R. M., Bertolucci, P. H. F., Borelli, W. V., Gomes, H. R., et al. (2024) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2024-c001 · Cited by 11
Escarcega, R. D., J., V. K. M., Kyriakopoulos, V. E., Ortiz, G. J., Gusdon, A. M., Fan, H., Peesh, P., Conesa, M. P. B., Colpo, G. D., Ahnstedt, H. W., et al. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106747 · Cited by 11
A Concise Overview of Biosensing Technologies for the Detection of Alzheimer's Disease Biomarkers
Talebi, M., Esmaeeli, H., Talebi, M., Farkhondeh, T., & Samarghandian, S. (2021) · Current Pharmaceutical Biotechnology · doi:10.2174/2666796702666210709122407 · Cited by 11
Motta, C., Donna, M. G. D., Bonomi, C. G., Assogna, M., Chiaravalloti, A., Mercuri, N. B., Koch, G., & Martorana, A. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01291-w · Cited by 11
Acharya, N. K., Grossman, H. C., Clifford, P. M., Levin, E. C., Light, K., Choi, H.-N., Swanson, R. L., Kosciuk, M. C., Venkataraman, V., Libon, D. J., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231028 · Cited by 13
Epistasis analysis links immune cascades and cerebral amyloidosis
Initiative, A. D. N., Benedet, A. L., Labbe, A., Lemay, P., Zimmer, E. R., Pascoal, T. A., Leuzy, A., Mathotaarachchi, S. S., Mohades, S., Shin, M., et al. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0436-z · Cited by 13
Proteomics Approach to Identify Biomarkers in Neurodegenerative Diseases
Nayak, A., Salt, G., Verma, S. K., & Kishore, U. (2015) · International review of neurobiology · doi:10.1016/bs.irn.2015.05.003 · Cited by 13
da Rosa, M. I., Perucchi, J. L., Medeiros, L. R., Fernandes, B. B., dos Reis, M. E. F., & Silva, B. R. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132264 · Cited by 11
Álzate, Ó., Osorio, C., DeKroon, R. M., Corcimaru, A., & Gunawardena, H. P. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt273 · Cited by 11
Cantero, J. L., Atienza, M., Sánchez‐Juan, P., Rodríguez‐Rodríguez, E., Vázquez‐Higuera, J. L., Pozueta, A., González‐Suárez, A., Vilaplana, E., Pegueroles, J., Montal, V., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.12.010 · Cited by 11
van der Spoel, E., van Vliet, N. A., & van Heemst, D. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100964 · Cited by 11
Gielis, K., Kennes, J., Dobbeleer, C. D., Puttemans, S., & Abeele, V. V. (2019) · IEEE International Conference on Healthcare Informatics (ICHI) · doi:10.1109/ichi.2019.8904511 · Cited by 12
Mimura, Y., Kurose, S., Takata, T., Tabuchi, H., Mimura, M., & Funayama, M. (2020) · BMC Neurology · doi:10.1186/s12883-020-01769-2 · Cited by 11
Contributions of Molecular and Optical Techniques to the Clinical Diagnosis of Alzheimer’s Disease
Bistaffa, E., Tagliavini, F., Matteini, P., & Moda, F. (2020) · Brain Sciences · doi:10.3390/brainsci10110815 · Cited by 11
Hajjar, I. M., Neal, R. M., Yang, Z., & Lah, J. J. (2024) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12581 · Cited by 10
Lumipulse-Measured Cerebrospinal Fluid Biomarkers for the Early Detection of Alzheimer Disease
Safransky, M., Groh, J. R., Blennow, K., Zetterberg, H., Tripodis, Y., Martin, B. M., Weller, J. L., Asken, B. M., Rabinovici, G. D., Qiu, W. W. Q., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000209866 · Cited by 10
Nabizadeh, F., Pirahesh, K., & Ramezannezhad, E. (2022) · Neurological Sciences · doi:10.1007/s10072-022-06440-x · Cited by 11
Multi-Omic Blood Biomarkers as Dynamic Risk Predictors in Late-Onset Alzheimer’s Disease
Bhalala, O. G., Watson, R., & Yassi, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021231 · Cited by 10
Jácome, D., Cotrufo, T., Andrés‐Benito, P., Lidón, L., Martı́, E., Ferrer, I., del Rı́o, J. A., & Gavı́n, R. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167187 · Cited by 10
Centiloid scale analysis for 18F-THK5351 PET imaging in Alzheimer’s disease
Yamao, T., Miwa, K., Wagatsuma, K., Shigemoto, Y., Sato, N., Akamatsu, G., Ito, H., & Matsuda, H. (2021) · Physica Medica · doi:10.1016/j.ejmp.2021.02.017 · Cited by 10
Vilca, B. N. C., Rodríguez‐Rojo, I. C., Torres-Simón, L., Cuesta, P., Carnes, A., Piñol‐Ripoll, G., Huerto, R. P., Tahan, N., & Maestú, F. (2022) · Clinical Neurophysiology · doi:10.1016/j.clinph.2022.08.007 · Cited by 10
Challenges in the development of companion diagnostics for neuropsychiatric disorders
Nikolcheva, T., Jäger, S., Bush, T. A., & Vargas, G. A. (2011) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.11.67 · Cited by 10
Michaud, T. L., Initiative, A. D. N., Kane, R. L., McCarten, J. R., Gaugler, J. E., Nyman, J. A., & Kuntz, K. M. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150066 · Cited by 10
Baker, K. G. (2016) · Diagnosis · doi:10.1515/dx-2015-0031 · Cited by 10
Fluid Biomarkers of Frontotemporal Lobar Degeneration
van der Ende, E. L., & Swieten, J. C. V. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-51140-1_9 · Cited by 11
Satake, Y., Kanemoto, H., Yoshiyama, K., Nakahama, R., Matsunaga, K., Shimosegawa, E., Morihara, T., Hashimoto, M., & Ikeda, M. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.742659 · Cited by 10
Yang, Y., Lorincz‐Comi, N. J., Li, M., & Zhu, X. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf250 · Cited by 9
Metadata
- Authors
- Tapiola, T., Alafuzoff, I., Herukka, S.-K., Parkkinen, L., Hartikainen, P., Soininen, H., & Pirttilä, T.
- Affiliations
- University of Eastern Finland (FI)
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2009-03-01
- Volume
- 66
- Issue
- 3
- Pages
- 382-9
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2075193321
- Cited by
- 896
- References
- 29
- Citations by year
- 2026: 18 · 2025: 27 · 2024: 45 · 2023: 27 · 2022: 34 · 2021: 78 · 2020: 89 · 2019: 75 · 2018: 60 · 2017: 59 · 2016: 51 · 2015: 65 · 2014: 48 · 2013: 63 · 2012: 41
- FWCI
- 32.16
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Archives of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Kuopion Yliopistollinen Sairaala
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, cerebrospinal fluid biomarkers, amyloid-beta 42, tau protein, phosphorylated tau, amyloid plaques, neurofibrillary tangles, diagnostic accuracy, lumbar CSF, neurodegeneration, alpha-synuclein, postmortem neuropathology, biomarker ratios, sensitivity and specificity
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Apolipoproteins E, Brain, Cross-Sectional Studies, Dementia, Female, Humans, Immunoassay, Male, Nervous System Diseases, Peptide Fragments, Retrospective Studies, ROC Curve, Logistic Models, Amyloid beta-Peptides, Silver Staining, tau Proteins, Statistics, Nonparametric, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
